TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01780285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitinol-framed lightweight PTFE mesh for hiatal repair
Description: The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair.
Study: NCT04573426

Intervention type: BEHAVIORAL
Intervention: Control vignette
Description: Short vignette meant to have no effect on emotion describing a generic promotion process
Study: NCT02523768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-F
Study: NCT01780285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partially absorbable lightweight mesh for hiatal repair
Description: A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure).
Study: NCT03249480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: 30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
Study: NCT02417129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: BI 695500 375 mg/M2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695500
Description: BI 695500 375 mg/M2
Study: NCT04572724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet
Description: Sacubitril/Valsartan will start at 50mg bid, when blood pressure can be tolerable, the dose will be gradually increased to 100mg bid after taking for 2-4 weeks, and then the target dose is gradually add to the 200mg bid after another 2-4 weeks. Ensure BP\>90/60mmHg, the minimum dose is 50mg bid if the patient can't tolerate higher dose but the blood pressure is stable at low dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAS Inhibitors
Description: RAS inhibitor group allows the use of a monodose of any ACEi or ARB. Ensure BP\>90/60mmHg, the minimum dose is half dose if the patient can't tolerate monodose but the blood pressure is stable at half dose.
Study: NCT01084525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104 (steroid) 12 mg
Description: Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
Study: NCT01266369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Study: NCT02523768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect
Study: NCT01349270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin perfusion
Description: patient who received monthly 2g/kg intravenous cure of immunoglobulin
Study: NCT02671149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Participants will receive two cups of 150ml plain water
Study: NCT01349270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
Study: NCT01680562

Intervention type: OTHER
Intervention: in-vivo skin tumor imaging via optical coherence tomography
Description: optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
Study: NCT04079322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal
Description: Participants will consume a meal containing a stable iron isotope following exercise or rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal
Description: Participants will consume a meal containing a stable iron isotope following exercise or rest.
Study: NCT03479840

Intervention type: PROCEDURE
Intervention: PCI
Description: treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
Study: NCT02596061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposit Contract
Description: Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deposit Contract
Description: Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Patients receive incentives for completing smoking cessation activities.
Study: NCT03181672

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate ganglion block
Description: Stellate ganglion block with 1% lidocaine 10ml
Study: NCT02596061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Patients receive incentives for completing smoking cessation activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Patients receive incentives for completing smoking cessation activities.
Study: NCT00597376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerefolin NAC (a medical food)
Description: Cerefolin NAC one tablet each day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cerefolin NAC placebo
Description: Placebo tablet once a day
Study: NCT02479581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Intravenous infusion of flucloxacillin sodium 1g an hour before operation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: 1. No routine bowel preparation;~2. Normal eating 1 days before the operation;~3. No drinking 2h and solid food 6h before the operation;~4. Drink 10% glucose 250ml 3h before operation ;~5. Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Emphasize the preoperative psychological preparation for patients.
Study: NCT00989742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 50mg od

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg od
Study: NCT00747006

Intervention type: DRUG
Group type: OTHER
Intervention: TI Inhalation Powder and Humalog (Amendment 1)
Description: Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI Inhalation Powder (original protocol)
Description: Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
Study: NCT02479581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
Study: NCT03181672

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Deltoid muscle injection with 1% lidocaine 10ml
Study: NCT02479581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Solu-Medrol®:5mg/kg intravenous infusion during the surgery;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: 1. Apply Transesophageal Echocardiography（TEE）after anesthesia induction;~2. Goal-directed fluid management.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: 1. Infusion of Human Albumin Grifol®20% 50ml;~2. Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));~3. Shorten the Cardio-pulmonary Bypass line；~4. Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Monitor urine volume closely, over 0.5ml/kg·h.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Protective ventilation strategy：Low tidal volume about 6\~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: Protective ventilation strategy：Low tidal volume about 6\~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
Study: NCT00724737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Presurgical MRI
Description: People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: functional MRI (fMRI) of the brain
Description: Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan.
Study: NCT02479581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: 1. Bilateral thoracic paravertebral block before induction of anesthesia;~2. Fast channel anesthesia:~   * Induction use Sufentanil 0.5\~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2\~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1\~0.4ug/kg·min, Propofol Injection 2\~6mg/kg·h, Sevoflurane 0.5\~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06\~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over.
Study: NCT04320914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity LASER Therapy
Description: The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J Duration of the treatment will be 8 minutes in one session/knee joint for each day for 3 days/week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen gel phonophoresis
Description: Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. Each treatment session will last for 8 min with one session each day for 3 days/week for 8 weeks.
Study: NCT04367740

Intervention type: DIAGNOSTIC_TEST
Intervention: To assess for development of IgG antibodies against SARS-CoV2
Description: Swabs will be collected to assess for COVID-19 if PPE supplies allow.
Study: NCT02802488

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care.
Study: NCT02104349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
Study: NCT00703781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromfenac ophthalmic solution
Description: sterile ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sterile ophthalmic solution
Study: NCT04159025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoreDx Pulmonary Mini-Forceps
Description: Manufactured by Boston Scientific
Study: NCT04218305

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Level Of Fetuin A
Study: NCT01428479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR121167 Solution
Description: GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR121167 Solution
Description: GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR121167 Solution
Description: GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution will be administered intravenously.
Study: NCT01579162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Description: The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Description: The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Description: The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Description: The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Description: The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days
Study: NCT00494195

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV1.tMCK.human-alpha-sarcoglycan- First cohort
Description: The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort
Description: The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
Study: NCT01968915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Description: Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
Study: NCT03678506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
Study: NCT03709914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01 100 mg/kg
Description: ZTI-01 intravenous (IV)
Study: NCT02479581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: 1. Drink water after 6h, 200ml once, 2\~3 times / day，~2. early ambulation，mobilization within 48 h,~3. Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；~4. Intravenous the lansoprazole 30mg q12h.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional control group
Description: Routine preoperative psychological preparation for patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS group
Description: After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
Study: NCT03709914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01 100 mg/kg
Description: ZTI-01 intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01 100 mg/kg
Description: ZTI-01 intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01 100 mg/kg
Description: ZTI-01 intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01 75 mg/kg
Description: ZTI-01 intravenous (IV)
Study: NCT00676806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood After Myeloablative Conditioning
Description: cyclophosphamide (60mg/m2 days -6 \& -5), fludarabine (25 mg/m2 days -7, -6, \& -5) and total body irradiation (days -3, -2, \& -1, total 1200 cGy) followed by cord blood infusion on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood After Reduced-Intensity Conditioning
Description: Extracorporeal Photopheresis (days -8 \& -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 \& -4), total body irradiation (days -3 \& -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
Study: NCT02005211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: Oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution
Study: NCT02576171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-therapy + ICBT
Description: The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
Study: NCT02545686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chest wall movement assessment without CPAP
Description: While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath hold assessment without CPAP
Description: While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest wall movement assessment with CPAP
Description: While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.